ESR1 and breast carcinoma: Therefore, whilst ER-negative cases were more frequently designated high risk than ER-positive cases (see above), there was no evidence in these exploratory analyses that Mammostrat® performed differently in ER-negative cases and untreated breast cancers when compared with ER-positive cases.